Mired In Politics: Emergency Contraceptives And Abortifacients

When the United States Food and Drug Administration (FDA) made an unprecedented announcement in July that, absent standard FDA-approval procedures, oral contraceptive pills in high doses are safe and effective for emergency contraception -- the so-called morning-after pill -- it was giving its imprimatur to a well-established use (T. Lewin, New York Times, July 1, 1996, page A1). An Institute of Medicine (IOM) report released in May (P.F. Harrison, A. Rosenfield, eds., Contraceptive Research a

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

When the United States Food and Drug Administration (FDA) made an unprecedented announcement in July that, absent standard FDA-approval procedures, oral contraceptive pills in high doses are safe and effective for emergency contraception -- the so-called morning-after pill -- it was giving its imprimatur to a well-established use (T. Lewin, New York Times, July 1, 1996, page A1).

An Institute of Medicine (IOM) report released in May (P.F. Harrison, A. Rosenfield, eds., Contraceptive Research and Development: Looking to the Future, Washington, D.C., National Academy Press, 1996) states that both combined estrogen/progestin and progestin-only pills are used as emergency contraceptives up to 72 hours post-coitus. The report also notes that mifepristone (RU 486) dosage and insertion of a copper-T intrauterine device (IUD) are given for emergency contraceptive use.

However, success rates for these treatments are markedly low, ranging from about 1 percent for both mifepristone and the IUD to 25 percent ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio